The Food and Drug Administration (FDA) said Thursday that updated regulations are needed for cannabidiol (CBD) and congress should create a path for such rules.
In a statement on Thursday, FDA Deputy Commissioner Dr. Janet Woodcock said that new regulations are necessary for CBD, which is a chemical in marijuana and does not include tetrahydrocannabinol (THC), which causes users to experience a high.
Woodcock said that the agency is ready to work with the United States Congress to establish a new regulation process for CBD. The agency also refused to accept three petitions from people that had asked the FDA to create rules to permit CBD items to be sold as dietary supplements.
The FDA regulates the medication Epidiolex, which has CBD in it and was the first medicine that the agency approved that had active drug material that came from marijuana. However, the agency said that a group looked at studies connected to Epidiolex, as well as other research, and decided that it is not clear how CBD items “could meet safety standards for dietary supplements or food additives.”
“For example, we have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm,” the statement noted.
The Washington Post reported that federal law holds that the active compounds used in prescription medication can’t also be food supplements. The FDA does not have much capability to increase the spread of CBD because of the existence of the…
